Dietary Supplements Containing Ephedrine Alkaloids; Reopening of the Comment Period; Correction

---
identifier: "/us/fr/03-6963"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Dietary Supplements Containing Ephedrine Alkaloids; Reopening of the Comment Period; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "03-6963"
section_name: "Dietary Supplements Containing Ephedrine Alkaloids; Reopening of the Comment Period; Correction"
positive_law: false
currency: "2003-03-25"
last_updated: "2003-03-25"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "03-6963"
document_type: "proposed_rule"
publication_date: "2003-03-25"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
cfr_references:
  - "21 CFR Part 111"
rin: "0910-AC51"
fr_citation: "68 FR 14360"
fr_volume: 68
docket_ids:
  - "Docket No. 95N-0304"
fr_action: "Proposed rule; correction."
---


#  Dietary Supplements Containing Ephedrine Alkaloids; Reopening of the Comment Period; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Proposed rule; correction.

**SUMMARY:**

The Food and Drug Administration is correcting a proposed rule that appeared in the *Federal Register* of March 5, 2003 (68 FR 10417). The document reopened for 30 days the comment period for a proposed rule entitled “Dietary Supplements Containing Ephedrine Alkaloids” (June 4, 1997, 62 FR 30678). The former document was published with an inadvertent error. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

Joyce Strong, Office of Policy and Planning (HF-27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7010.

**SUPPLEMENTARY INFORMATION:**

In FR Doc. 03-5072, appearing on page 10417 in the *Federal Register* of Wednesday, March 5, 2003, the following correction is made:

1. On page 10420, in the second column, reference 7 is corrected to read:

7. Shekelle, P., S. Morton, M. Maglione, et al., “Ephedra and Ephedrine for Weight Loss and Athletic Performance Enhancement: Clinical Efficacy and Side Effects,” Evidence Report/Technology Assessment No. 76 (Prepared by Southern California Evidence-based Practice Center, RAND, under Contract No. 290-97-0001, Task Order No. 9), Agency for Healthcare Research and Quality, February 2003, Publication No. 03-E022, Rockville, MD.

Dated: March 17, 2003.

William K. Hubbard,

Associate Commissioner for Policy and Planning.